ArsenalBio is a biotechnology company which offers programmable cell therapy solutions to healthcare organizations. This company was founded by Ken Drazan MD, Nick Haining, John Wherry Ph.D, Bradley Bernstein Ph.D, and Kole Roybal Ph.D in 2019 and is headquartered in South San Francisco, CA. ArsenalBio’s platform is designed to develop and optimize T cell therapies, with the goal of treating cancer more effectively. The company seeks to enable precise control over T cells to enhance patient outcomes in immunotherapy treatments.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
09/04/2024 | Series C | $327.5MM | $xx.xx | $1.66B | Arch Venture Partners, Bristol-Myers Squibb, Byers Capital, Hitachi Ventures, Kleiner Perkins, Luma Group, Milky Way Investments Group, Nvidia, Parker Institute For Cancer Immunotherapy, Regeneron, Rock Springs Capital, Softbank, T. Rowe Price Associates, Westlake Village Biopartners | |
Price per Share
$xx.xx
Shares Outstanding
17,626,627
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Arch Venture Partners, Bristol-Myers Squibb, Byers Capital, Hitachi Ventures, Kleiner Perkins, Luma Group, Milky Way Investments Group, Nvidia, Parker Institute For Cancer Immunotherapy, Regeneron, Rock Springs Capital, Softbank, T. Rowe Price Associates, Westlake Village Biopartners
|
||||||
09/06/2022 | Series B | $253.81MM | $xx.xx | $1.03B | Bristol-Myers Squibb, Byers Capital, Emerson Collective Investments, Euclidean Capital, Green Sands, Hitachi Ventures, Kleiner Perkins, Parker Institute For Cancer Immunotherapy, Sixth Street, Softbank, Ucsf Foundation, Waycross Ventures, Westlake Village Biopartners | |
Price per Share
$xx.xx
Shares Outstanding
17,207,230
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Bristol-Myers Squibb, Byers Capital, Emerson Collective Investments, Euclidean Capital, Green Sands, Hitachi Ventures, Kleiner Perkins, Parker Institute For Cancer Immunotherapy, Sixth Street, Softbank, Ucsf Foundation, Waycross Ventures, Westlake Village Biopartners
|
||||||
10/17/2019 | Series A | $86.02MM | $xx.xx | $191.15MM | Euclidean Capital, Kleiner Perkins, Osage Venture Partners, Parker Institute For Cancer Immunotherapy, Ucsf Foundation Investment Company, University Of California, Westlake Village Biopartners | |
Price per Share
$xx.xx
Shares Outstanding
18,967,560
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Euclidean Capital, Kleiner Perkins, Osage Venture Partners, Parker Institute For Cancer Immunotherapy, Ucsf Foundation Investment Company, University Of California, Westlake Village Biopartners
|